Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Biosimilars Hurdle: Winning Over Physicians

This article was originally published in The Pink Sheet Daily

Executive Summary

Data necessary for regulatory approval may not be sufficient for prescribers, Pfizer’s Sophie Opdyke tells Pharmaceutical Strategy Conference.

You may also be interested in...



Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?

Biosimilarity Margin Change By FDA Might Give Amgen's Avastin Copy Big Head Start

Did Amgen/Allergan get a lucky break by already having their clinical trial enrolled and being unable to increase the sample size for their Avastin biosimilar?

Earnings Updates, In Brief: Momenta, Acorda, Sangamo, Lundbeck, Actelion, Alnylam, Seattle Genetics

Year-end earnings reports from the biotech crowd show movement in the biosimilar field, faith in RNAi, high value for rare disease approaches and strategies to defend and grow primary assets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel